Status:
COMPLETED
A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).
Lead Sponsor:
AstraZeneca
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
The primary objective of the study is to collect epidemiological data on EGFR mutation status \[M+(mutation positive), M-(mutation negative)\] in a population of predominantly Caucasian ethnicity, and...
Eligibility Criteria
Inclusion
- Signed written informed consent.
- Female or male aged 18 years or above.
- Histologically confirmed locally advanced or metastatic NSCLC (stage IIIB/IV).
- Patients receiving 1st-line treatment for IIIB/IV NSCLC.
- Patients with known EGFR mutation status (i.e. patients must be either EGFR M+, EGFR M- or EGFR Mx).
- Tumour not amenable to curative surgery or radiotherapy.
Exclusion
- 1\. Mixed histology of small cell and non-small cell lung cancer.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
589 Patients enrolled
Trial Details
Trial ID
NCT01153399
Start Date
October 1 2010
End Date
December 1 2014
Last Update
November 20 2015
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Athens, Athens, Greece
2
Research Site
Crete, Crete, Greece
3
Research Site
Ioannina, Ioannina, Greece
4
Research Site
Kavala, Kavala, Greece